Urinary Stress Incontinence
Conditions
Keywords
Muscle Precursor Cells
Brief summary
The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addition, the demand for high-quality products with an optimal safety profile is increasing. The proposed cell treatment is the first therapeutical option with the possibility to revert the underlying condition. The investigators expect that this healing response will be achieved with minimal side effects justifying the addional costs and complexity.
Detailed description
muscle precursor cells (MPCs) will be isolated from biopsies of the lower leg of patients, seeded, expanded and cultivated in vitro in a GMP facility to generate vital muscle cells dedicated for implantation. These muscle cells exhibit myogenic phenotype (IHC and flow cytometry) and therefore morphological and histological prerequisites approximating the properties of native skeletal muscle tissue. The muscle progenitor cells shall be applied in external sphincter muscle for the treatment of patients with stress urinary incontinence.
Interventions
OTHERMuscle Precursor Cells (MPCs), ATMP
The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
Sponsors
University Hospital Tuebingen
Salzburger Landeskliniken
University of Zurich
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Open-label, monocentric, first-in-man trial to assess safety and tolerability of a new therapeutic strategy for stress urinary incontinence based on the implantation of muscle precursor cells (MPCs) 40 female patients suffering from urinary incontinence since at least 6 months (predominant clinical diagnosis of SUI) and who are candidate for a surgical treatment will be included . All patients are treated by the same product: Autologous MPCs. After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy.
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
Adult women 20y-60y * Incontinence \>/= grade I since at least 6 months * Predominant clinical diagnosis of SUI * Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons). * Post void residual volume of \<100 ml (exclusion of overflow incontinence) * Can independently use toilet without difficulty * Capacity to answer the questionnaires of evaluation * Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis * Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed
Exclusion criteria
* History of anti-incontinence or prolapse surgery. * Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract: * Clinically significant cystocele or rectocele * Ureteric bladder, urethral or rectal fistula * Uncorrected congenital abnormality leading to urinary incontinence * Interstitial cystitis * Urinary urgency that results in leakage (as a predominant symptom) * Adult enuresis * Urodynamically proven detrusor instability * Sensory urgency defined as first sensation of bladder fill (urge to void) of \<100 ml; bladder capacity of \<300 ml * No sensation at any time during the simple filling cystometry procedure * Known urethral stenosis (ureterocystoscopy) or urethral diverticulum * History of urogenital cancer or history of pelvic radiotherapy * Women who are pregnant, breast feeding or \<12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population. * Untreated symptomatic urinary tract infection * Fever (as defined by ≥ 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days * Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment * Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results. * Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products * Known allergy or intolerance of Penicillin or Streptomycin * Known genetically determined or acquired muscular disease. * Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism). * Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study. * Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs. * Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of clinically relevant Adverse Events of MPCs or related to cell injection | at 3 months post-implantation | Number of clinically relevant findings related to cell injection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of MPC injection measured by post-void residual volume | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation | post-void residual volume |
| Efficacy of MPC injection measured by Uroflowmetry | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation | Uroflowmetry: urinary flow pattern |
| Efficacy of MPC injection measured by Urodynamic Evaluation | at baseline, 3 months and 6 months post-implantation | 2 Filling-Cystometries |
| Efficacy of MPC injection measured by 1h pad test | at baseline, 1 month, 3 months and 6 months post-implantation | 1h pad test |
| Feasibility of MPC injection | day of implantation | Percentage of subjects with successful injection |
| Efficacy measured by average score of Visual Analog Scale of degree of suffering | at baseline, 1 month, 3 months and 6 months post-implantation | Visual Analog Scale of degree of suffering. Range 0 (worst) to 10 (best) |
| Efficacy measured by average score of Quality of Life | at baseline, 1 month, 3 months and 6 months post-implantation | Quality of Life Score, using SF-36v2™ Health Survey |
| Efficacy | 6 months post-implantation | Number for (planned) subsequent incontinence surgery |
| Number of patients with abnormal laboratory values and/or Adverse Events that are related to MPC injection | at baseline, day of implantation, 1 month, 3 months and 6 months post-implantation | Safety measures (ultrasound, physical examination, laboratroy) |
| Efficacy measured by average Incontinence Score | at baseline, 1 month, 3 months and 6 months post-implantation | Incontinence Score. Range from 0 (no incentinence) to 21 (highly incontinent) |
Countries
Switzerland
Outcome results
None listed